Robert Soiffer, MD
Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
Chief, DF/BWCC Division of Hematologic Malignancies and Co-Chief, DF/BWCC Adult Stem Cell Transplantation Program
Professor of Medicine, Harvard Medical School
Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident.
He joined Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in 1988, after completing a medical oncology fellowship. Dr. Soiffer has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of
Blood and Marrow Transplantation.
Irene Ghobrial, MD
Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
Director, Michele & Stephen Kirsch Laboratory, Dana-Farber Cancer Institute
Medical Oncologist, DF/BWCC Jerome Lipper Multiple Myeloma Center
Associate Professor of Medicine, Harvard Medical School
Dr. Ghobrial is a physician-scientist who specializes in early precursor conditions of multiple myeloma and Waldenström's Macroglobulinemia, specifically MGUS and smoldering diseases. Her
research laboratory interests are in the area of cell trafficking and cell metastasis in B cell malignancies and the malignant bone marrow niches. She is the principal investigator of several clinical trials in both
multiple myeloma and Waldenström's Macroglobulinemia.
David P. Steensma, MD
Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
Medical Oncologist, DF/BWCC Adult Leukemia Program
Associate Professor of Medicine, Harvard Medical School
Dr. Steensma's primary area of clinical activity and research focus is the myelodysplastic syndromes (MDS) and related conditions. His research activity includes development of new therapies, as well as discovery of new somatic genetic mutations important
in the pathobiology of this difficult and poorly-understood group of smoldering myeloid neoplasms.
Dr. Steensma is also involved in collaborations with several laboratory-based scientists, particularly
Benjamin Ebert, MD, PhD and
Mark Fleming, MD, DPhil, to try to discover new pathways disturbed in MDS and related disorders – with the goal of finding pathways that can be exploited therapeutically.
Benjamin Ebert, MD, PhD
Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
Medical Oncologist, DF/BWCC
Assistant Professor of Medicine, Harvard Medical School
Dr. Ebert's
laboratory studies the biology and genetics of hematologic malignancies and other hematologic disorders. His group employs a range of genomic and proteomic
technologies, as well as classical cellular and molecular biology approaches, to investigate the molecular basis of specific human diseases.
Major focuses of the laboratory are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Ebert identified a gene that plays a central role in the pathophysiology of MDS with deletions of chromosome 5q. These findings revealed a molecular
link between del(5q) MDS and congenital bone marrow syndromes such as Diamond Blackfan anemia. The Ebert laboratory has also definied sets of mutations in MDS that are associated with various disease phenotypes, including overall survival and response
to specific therapies.
Investigators by Disease Group
Monoclonal Gammopathy of Undermined Significance (MGUS) and Smoldering Multiple Myeloma
Core leaders
Irene Ghobrial, MD
Jacob Laubach, MD
Nikhil Munshi, MD
Robert Schlossman, MD
Other team members
Kenneth Anderson, MD
Claudia Paba-Prada, MD
Paul Richardson, MD
Immunoglobulin (Ig)M-MGUS and Smoldering Waldenström's Macroglobulinemia
Core leaders
Jorge Castillo, MD
Irene Ghobrial, MD
Other team members
Steven Treon, MD, PhD
Myelodysplastic Syndrome (MDS)
Core leaders
Benjamin Ebert, MD, PhD
R. Coleman Lindsley, MD, PhD
David Steensma, MD
Other team members
Daniel DeAngelo, MD, PhD
Richard Stone, MD
Myeloproliferative Neoplasms (MPN)
Core leaders
Ann Mullally, MD
David Steensma, MD
Other team members
Martha Wadleigh, MD
Monoclonal B Cell Lymphocytosis (MBL) and Early Chronic Lymphocytic Leukemia (CLL)
Core leader
Matthew Davids, MD
Other team members
Jennifer Brown, MD, PhD
Catherine Wu, MD
Low-Grade Lymphomas, including Early-Stage Follicular Lymphoma
Core leader
Ann LaCasce, MD
Other team members
Jennifer Brown, MD, PhD
Arnold Freedman, MD
Catherine Wu, MD
Other Precursor Conditions or Clonal Genetic Abnormalities of the Bone Marrow/Blood
Core leaders
Benjamin Ebert, MD, PhD
Aric Parnes, MD
Other team members
Nancy Berliner, MD